title: Association between the NBS1 Glu185Gln polymorphism and breast cancer risk: a meta-analysis.
abstract: Nijmegen breakage syndrome 1 (NBS1), a vital DNA repair protein in the homologous recombination repair pathway and a signal modifier in the intra-S phase checkpoint, plays a critical role in cellular response to DNA damages and the maintenance of genomic stability. The NBS1 Glu185Gln (NBS1 E185Q, NBS1 8360G>C, rs1805794) polymorphism has been indicated to be involved in the development of cancer, but results of previous individual studies on the association between NBS1 Glu185Gln polymorphism and breast cancer risk remain controversial and inconclusive. Our meta-analysis investigated this association for the first time by pooling the odds ratios with corresponding 95 % confidence intervals (95 % CIs) of all individual publications available to date. Overall, 14 separate studies with 6,642 cases and 7,138 controls were finally included into the present meta-analysis after a comprehensive literature search of the PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases up to October 21, 2012. Overall analysis and subgroup analyses by ethnicity and source of controls were performed. Meta-analysis of total studies showed that the NBS1 Glu185Gln variant carriers were not susceptible to breast cancer (ORGln vs. Glu = 1.05, 95 % CI 0.80-1.39, P OR = 0.719; OR Gln/Gln vs. Glu/Glu = 0.82, 95 % CI 0.62-1.08, P OR = 0.154; OR Glu/Gln vs. Glu/Glu = 1.00, 95 % CI 0.90-1.13, P OR = 0.939; ORGln/Gln + Glu/Gln vs. Glu/Glu = 0.96, 95 % CI 0.83-1.11, P OR = 0.551; ORGln/Gln vs. Glu/Glu + Glu/Gln = 0.84, 95 % CI 0.67-1.05, P OR = 0.134). Similar results were observed in heterogeneity-adjusted meta-analysis of all studies. Furthermore, subgroup analyses by ethnicity and source of controls did not identify any appreciable relationship of the NBS1 Glu185Gln polymorphism with breast cancer susceptibility in any populations. Sensitivity analysis by sequentially omitting individual studies confirmed the stability and reliability of our results. Our meta-analysis of currently available data shows no association between the NBS1 Glu185Gln polymorphism and breast cancer risk.
authors: Department of Breast Surgery and Surgical Oncology, Research Unit of General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, 110001, China. doctoryao66@yeah.net
authors: Fan
authors: F
authors: Yao
authors: Yue
authors: Y
authors: Fang
authors: Bo
authors: B
authors: Chen
authors: Feng
authors: F
authors: Jin
authors: Shubao
authors: S
authors: Wang
mesh_terms: D001943:Breast Neoplasms / Q000209:etiology*; D016022:Case-Control Studies; D018797:Cell Cycle Proteins / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D012307:Risk Factors
chemical_list: D018797:Cell Cycle Proteins; C112156:NBN protein, human; D009687:Nuclear Proteins
references: Hum Mol Genet. 2002 Jun 1;11(12):1399-407
references: 12023982
references: Genome Dyn. 2006;1:191-205
references: 18724061
references: Genes Chromosomes Cancer. 2002 Nov;35(3):282-6
references: 12353271
references: BMJ. 1998 Feb 7;316(7129):469; author reply 470-1
references: 9492685
references: Breast Cancer Res Treat. 2010 May;121(1):147-56
references: 19714462
references: J Appl Genet. 2010;51(3):343-52
references: 20720310
references: Science. 1994 Oct 7;266(5182):66-71
references: 7545954
references: Obstet Gynecol. 2010 Dec;116(6):1410-1421
references: 21099612
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Adv Biophys. 2004;38(Complete):65-80
references: 15476893
references: Climacteric. 2012 Jun;15(3):241-9
references: 22612610
references: Eur J Haematol. 2011 Mar;86(3):199-205
references: 21166880
references: Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2326-34
references: 16214912
references: Carcinogenesis. 2006 Nov;27(11):2209-16
references: 16714331
references: Carcinogenesis. 2010 Jul;31(7):1264-71
references: 20478923
references: Mol Cell Biol. 2009 Feb;29(4):1000-6
references: 19075003
references: Int J Biometeorol. 2003 Aug;47(4):227-9
references: 12687451
references: Cancer Epidemiol. 2010 Feb;34(1):85-92
references: 20004634
references: Nat Genet. 2006 Aug;38(8):873-5
references: 16832357
references: Carcinogenesis. 2005 Jul;26(7):1263-71
references: 15746160
references: Asian Pac J Cancer Prev. 2012;13(7):3431-6
references: 22994773
references: BMC Cancer. 2009 Jun 12;9:181
references: 19523210
references: Science. 2004 Apr 2;304(5667):93-6
references: 15064416
references: Biometrika. 1950 Dec;37(3-4):256-66
references: 14801052
references: Oncol Rep. 2004 Apr;11(4):917-22
references: 15010895
references: Carcinogenesis. 2008 Nov;29(11):2132-8
references: 18701435
references: BMC Cancer. 2009 Apr 24;9:124
references: 19393077
references: BMJ. 2000 Sep 9;321(7261):624-8
references: 10977847
references: Nature. 1995 Dec 21-28;378(6559):789-92
references: 8524414
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Nat Genet. 1998 Jun;19(2):179-81
references: 9620777
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: Ann Surg. 2003 Apr;237(4):474-82
references: 12677142
references: Lung Cancer. 2006 Dec;54(3):285-92
references: 17034901
references: Nat Genet. 2007 Feb;39(2):165-7
references: 17200668
references: Clin Chim Acta. 2005 Sep;359(1-2):150-5
references: 16002061
references: DNA Cell Biol. 2012 May;31(5):678-82
references: 22070649
references: Cell. 1998 May 1;93(3):467-76
references: 9590180